Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PER2 | O15055 | 6/20 | 0.37 |
| ▸ | CRY1 | Q16526 | 5/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582383 | 0.70 | KMT2A (0.41) | KMT2ALMNAMAPTWDR5ALDH1A1 | |
| SCHEMBL6204631 | 0.68 | KMT2A (0.43) | KMT2AALDH1A1SMN1; SMN2SLC6A4SLC6A3 | |
| SCHEMBL6579690 | 0.67 | MAPT (0.33) | PER2CRY1CRY2LMNAMAPT | |
| SCHEMBL7539835 | 0.66 | KMT2A (0.74) | KMT2ALMNAMAPTALDH1A1SLC6A4 | |
| SCHEMBL624786 | 0.64 | KMT2A (0.47) | KMT2ASLC6A4SLC6A3 | |
| SCHEMBL2515106 | 0.64 | BDKRB1 (0.48) | KMT2ALMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7387709 | 0.64 | KMT2A (0.74) | KMT2ALMNAMAPTALDH1A1SLC6A4 | |
| SCHEMBL6213755 | 0.63 | GAA (0.40) | KMT2APER2CRY1CRY2NPSR1 | |
| SCHEMBL29858803 | 0.63 | PDE4B (0.48) | KMT2AWDR5SMN1; SMN2MEN1 | |
| SCHEMBL6313636 | 0.63 | KMT2A (0.72) | KMT2ALMNAMAPTALDH1A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146044-B1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6452015-B2 | FOR TREATMENT OF ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | disclosed |
| EP-1146044-A1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | HRH4, HTR4, CNR1 | KMT2A 1425/4885PER2 2055/4885CRY1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.